Skip to main content
SpringerLink
Log in

Increase in serum vimentin levels in patients with glioma and its correlation with prognosis of patients with glioblastoma

  • Research
  • Published:
Neurosurgical Review Aims and scope Submit manuscript

Abstract

Early diagnosis of glioma is of great value to improve prognosis. We focused on serum vimentin levels as a useful biomarker for preoperative diagnosis. The aim of this study was to determine whether serum vimentin levels in patients with glioma are significantly higher than those of healthy adult volunteer and whether the serum vimentin level is associated with overall survival (OS) in patients with glioblastoma (GBM). This study included 52 consecutive patients with newly diagnosed glioma and a control group of 13 healthy adult volunteers. We measured serum vimentin levels in blood samples obtained from patients with glioma preoperatively and a control group. Furthermore, we investigated the correlation between serum vimentin levels and OS in patients with GBM. The serum vimentin levels of patients with glioma were significantly higher than those of the control group. The serum vimentin level of 2.9 ng/ml was the optimal value for differentiating patients with glioma from the control group with a sensitivity of 92.3% and specificity of 88.5%. The serum vimentin levels correlated significantly with immunoreactivity for survivin. In 27 patients with GBM, serum vimentin levels (cutoff value, median value 53.3 ng/ml) correlated with OS in univariate and multivariate analyses. Our study revealed that serum vimentin levels of patients with glioma are significantly higher than those of the control group. Therefore, we believe that serum vimentin level might be a useful and practical biomarker for preoperative diagnosis of glioma. Furthermore, high serum vimentin levels correlated significantly with shorter OS in patients with GBM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability

Not applicable.

References

  1. Aggarwal S, Singh B, Sharma SC, Das SN (2022) Circulating vimentin over-expression in patients with oral sub mucosal fibrosis and oral squamous cell carcinoma. Indian J Otolaryngol Head Neck Surg 74:510–515. https://doi.org/10.1007/s12070-021-03018-5

    Article  PubMed  PubMed Central  Google Scholar 

  2. Andersson KM, Svensson MN, Erlandsson MC, Jonsson IM, Bokarewa MI (2015) Down-regulation of survivin alleviates experimental arthritis. J Leukoc Biol 97:135–145. https://doi.org/10.1189/jlb.3A0714-317R

    Article  PubMed  CAS  Google Scholar 

  3. Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R (2017) Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. Int J Biol Mark 32:e126–e131. https://doi.org/10.5301/jbm.5000229

    Article  CAS  Google Scholar 

  4. Brain Tumor Registry of Japan (2005–2008) (2017) Neurol Med Chir (Tokyo) 57:9–102. https://doi.org/10.2176/nmc.sup.2017-0001

  5. Chen MH, Lu C, Sun J, Chen XD, Dai JX, Cai JY, Chen XL (2016) Diagnostic and prognostic value of serum vitronectin levels in human glioma. J Neurol Sci 371:54–59. https://doi.org/10.1016/j.jns.2016.10.022

    Article  PubMed  CAS  Google Scholar 

  6. DeWitt JC, Mock A, Louis DN (2017) The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol 30:643–649. https://doi.org/10.1097/WCO.0000000000000490

    Article  PubMed  Google Scholar 

  7. Egger J, Kapur T, Fedorov A, Pieper S, Miller JV, Veeraraghavan H, Freisleben B, Golby AJ, Nimsky C, Kikinis R (2013) GBM volumetry using the 3D Slicer medical image computing platform. Sci Rep 3:1364. https://doi.org/10.1038/srep01364

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Franke WW, Schmid E, Osborn M, Weber K (1978) Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci U S A 75:5034–5038. https://doi.org/10.1073/pnas.75.10.5034

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Fuchs E, Weber K (1994) Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63:345–382. https://doi.org/10.1146/annurev.bi.63.070194.002021

    Article  PubMed  CAS  Google Scholar 

  10. Fujii Y, Muragaki Y, Maruyama T, Nitta M, Saito T, Ikuta S, Iseki H, Hongo K, Kawamata T (2018) Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. J Neurosurg 129:1–9. https://doi.org/10.3171/2017.3.JNS162383

    Article  PubMed  Google Scholar 

  11. Fukui A, Muragaki Y, Saito T, Maruyama T, Nitta M, Ikuta S, Kawamata T (2017) Volumetric analysis using low-field intraoperative magnetic resonance imaging for 168 newly diagnosed supratentorial glioblastomas: effects of extent of resection and residual tumor volume on survival and recurrence. World Neurosurg 98:73–80. https://doi.org/10.1016/j.wneu.2016.10.109

    Article  PubMed  Google Scholar 

  12. Hilbert M, Kuzman P, Mueller WC, Meixensberger J, Nestler U (2022) Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study. Sci Rep 12:16981. https://doi.org/10.1038/s41598-022-21216-1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Huo Y, Zheng Z, Chen Y, Wang Q, Zhang Z, Deng H (2016) Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Oncotarget 7:45876–45888. https://doi.org/10.18632/oncotarget.9970

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ivaska J, Pallari HM, Nevo J, Eriksson JE (2007) Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 313:2050–2062. https://doi.org/10.1016/j.yexcr.2007.03.040

    Article  PubMed  CAS  Google Scholar 

  15. Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, Xu SS (2015) Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer 112:1241–1246. https://doi.org/10.1038/bjc.2015.91

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Lan F, Yue X, Xia T (2020) Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. Oncol Lett 19:1967–1974. https://doi.org/10.3892/ol.2020.11249

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Lilina AV, Leekens S, Hashim HM, Vermeire PJ, Harvey JN, Strelkov SV (2022) Stability profile of vimentin rod domain. Protein Sci 31:e4505. https://doi.org/10.1002/pro.4505

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Liu Y, Zhang J, Wang D, Yang X (2019) Serum ROCK1 mRNA is of great diagnostic value for glioma patients. Medicine (Baltimore) 98:e15413. https://doi.org/10.1097/MD.0000000000015413

    Article  PubMed  CAS  Google Scholar 

  19. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD (2002) Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9:1334–1342. https://doi.org/10.1038/sj.cdd.4401091

    Article  PubMed  CAS  Google Scholar 

  20. Maruno M, Yoshimine T, Ushio Y, Hayakawa T, Jamshidi J, Arita N, Bitoh S, Mogami H (1987) Immunohistochemical study of human brain tumors with vimentin and astroprotein (GFAP). No To Shinkei 39:579–585

    PubMed  CAS  Google Scholar 

  21. Morokoff A, Jones J, Nguyen H, Ma C, Lasocki A, Gaillard F, Bennett I, Luwor R, Stylli S, Paradiso L, Koldej R, Paldor I, Molania R, Speed TP, Webb A, Infusini G, Li J, Malpas C, Kalincik T, Drummond K, Siegal T, Kaye AH (2020) Serum microRNA is a biomarker for post-operative monitoring in glioma. J Neurooncol 149:391–400. https://doi.org/10.1007/s11060-020-03566-w

    Article  PubMed  CAS  Google Scholar 

  22. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131

    Article  PubMed  PubMed Central  Google Scholar 

  23. Qu S, Chen Z, Liu B, Liu J, Wang H (2021) N6-methyladenine-related genes affect biological behavior and the prognosis of glioma. Cancer Med 10:98–108. https://doi.org/10.1002/cam4.3574

    Article  PubMed  CAS  Google Scholar 

  24. Qu S, Qiu O, Hu Z (2021) The prognostic factors and nomogram for patients with high-grade gliomas. Fundam Res 1:824–828. https://doi.org/10.1016/j.fmre.2021.07.005

    Article  CAS  Google Scholar 

  25. Ramos I, Stamatakis K, Oeste CL, Perez-Sala D (2020) Vimentin as a multifaceted player and potential therapeutic target in viral infections. Int J Mol Sci 21. https://doi.org/10.3390/ijms21134675

  26. Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164–171. https://doi.org/10.1016/j.canlet.2006.03.007

    Article  PubMed  CAS  Google Scholar 

  27. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K (2007) Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol 82:193–198. https://doi.org/10.1007/s11060-006-9267-1

    Article  PubMed  CAS  Google Scholar 

  28. Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, Aki T, Iseki H, Kurisu K, Okada Y (2013) 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol 34:85–91. https://doi.org/10.3174/ajnr.A3173

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Saito T, Muragaki Y, Maruyama T, Komori T, Nitta M, Tsuzuki S, Fukui A, Kawamata T (2019) Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy. Neurosurg Rev. https://doi.org/10.1007/s10143-019-01185-2

    Article  PubMed  Google Scholar 

  30. Saito T, Muragaki Y, Maruyama T, Tamura M, Nitta M, Tsuzuki S, Konishi Y, Kamata K, Kinno R, Sakai KL, Iseki H, Kawamata T (2016) Difficulty in identification of the frontal language area in patients with dominant frontal gliomas that involve the pars triangularis. J Neurosurg 125:803–811. https://doi.org/10.3171/2015.8.JNS151204

    Article  PubMed  Google Scholar 

  31. Saito T, Muragaki Y, Shioyama T, Komori T, Maruyama T, Nitta M, Yasuda T, Hosono J, Okamoto S, Kawamata T (2019) Malignancy index using intraoperative flow cytometry is a valuable prognostic factor for glioblastoma treated with radiotherapy and concomitant temozolomide. Neurosurgery 84:662–672. https://doi.org/10.1093/neuros/nyy089

    Article  PubMed  Google Scholar 

  32. Saito T, Muragaki Y, Tamura M, Maruyama T, Nitta M, Tsuzuki S, Fukuchi S, Ohashi M, Kawamata T (2019) Awake craniotomy with transcortical motor evoked potential monitoring for resection of gliomas in the precentral gyrus: utility for predicting motor function. J Neurosurg 1–11. https://doi.org/10.3171/2018.11.JNS182609

  33. Saito T, Sugiyama K, Takeshima Y, Amatya VJ, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K (2018) Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurosurg 128:679–684. https://doi.org/10.3171/2016.11.JNS162326

    Article  PubMed  CAS  Google Scholar 

  34. Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM (2010) Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res 9:1923–1930. https://doi.org/10.1021/pr901085z

    Article  PubMed  CAS  Google Scholar 

  35. Turner JD, Williamson R, Almefty KK, Nakaji P, Porter R, Tse V, Kalani MY (2010) The many roles of microRNAs in brain tumor biology. Neurosurg Focus 28:E3. https://doi.org/10.3171/2009.10.FOCUS09207

    Article  PubMed  Google Scholar 

  36. van Asperen JV, Fedorushkova DM, Robe P, Hol EM (2022) Investigation of glial fibrillary acidic protein (GFAP) in body fluids as a potential biomarker for glioma: a systematic review and meta-analysis. Biomarkers 27:1–12. https://doi.org/10.1080/1354750X.2021.2006313

    Article  PubMed  Google Scholar 

  37. Wei X, Chen D, Lv T, Li G, Qu S (2016) Serum MicroRNA-125b as a potential biomarker for glioma diagnosis. Mol Neurobiol 53:163–170. https://doi.org/10.1007/s12035-014-8993-1

    Article  PubMed  CAS  Google Scholar 

  38. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. https://doi.org/10.1056/NEJMra0708126

    Article  PubMed  CAS  Google Scholar 

  39. Willems E, Dedobbeleer M, Digregorio M, Lombard A, Goffart N, Lumapat PN, Lambert J, Van den Ackerveken P, Szpakowska M, Chevigne A, Scholtes F, Rogister B (2019) Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration. Oncogene 38:73–87. https://doi.org/10.1038/s41388-018-0437-3

    Article  PubMed  CAS  Google Scholar 

  40. Yang F, Ma J, Wan J, Ha W, Fang C, Lu H, Zhang W (2020) Epithelial-mesenchymal transition of circulating tumor cells in prostate cancer is promoted by survivin. J Int Med Res 48:300060519892395. https://doi.org/10.1177/0300060519892395

    Article  PubMed  CAS  Google Scholar 

  41. Zhao J, Zhang L, Dong X, Liu L, Huo L, Chen H (2018) High Expression of vimentin is associated with progression and a poor outcome in glioblastoma. Appl Immunohistochem Mol Morphol 26:337–344. https://doi.org/10.1097/PAI.0000000000000420

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Takashi Sakayori, Department of Pathology, Tokyo Women’s Medical University, Tokyo, Japan, for the immunohistochemical staining and Saori Okamoto, Shinjuku Hiro Clinic, Tokyo, Japan, for the ELISA method. We would like to thank Editage (www.editage.com) for the English language editing.

Funding

This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant No. 21K09138.

Author information

Author notes

  1. Taiichi Saito and Yoshihiro Muragaki contributed equally to this work.

Authors and Affiliations

  1. Department of Neurosurgery, Tokyo Women’s Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, 162-8666, Japan

    Taiichi Saito, Yoshihiro Muragaki, Masayuki Nitta, Shunsuke Tsuzuki, Shunichi Koriyama, Bunto Ro & Takakazu Kawamata

  2. Center for Advanced Medical Engineering Research and Development (CAMED), Kobe University, Kobe City, Japan

    Yoshihiro Muragaki

  3. Department of Central Clinical Laboratory, Tokyo Women’s Medical University, Tokyo, Japan

    Asuka Komori

Authors
  1. Taiichi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Muragaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asuka Komori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayuki Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shunsuke Tsuzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunichi Koriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bunto Ro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takakazu Kawamata
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: Taiichi Saito, Yoshihiro Muragaki; formal analysis and investigation: Asuka Komori, Masayuki Nitta; writing—original draft preparation: Taiichi Saito; writing—review and editing: Yoshihiro Muragaki, Taiichi Saito, Takakazu Kawamata; funding acquisition: Taiichi Saito; resources: Shunsuke Tsuzuki, Shunichi Koriyama, Bunto Ro; visualization: Shunsuke Tsuzuki, Shunichi Koriyama; supervision: Takakazu Kawamata; approved the final version: all authors.

Corresponding author

Correspondence to Taiichi Saito.

Ethics declarations

Ethics approval

Ethical approval was obtained from the ethics committee at Tokyo Women’s Medical University (No. 2621-R2).

Consent to participate

We obtained informed consent from all patients and healthy adult volunteers. To protect patient privacy, we removed all identifiers from our records on the completion of our analyses.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saito, T., Muragaki, Y., Komori, A. et al. Increase in serum vimentin levels in patients with glioma and its correlation with prognosis of patients with glioblastoma. Neurosurg Rev 46, 202 (2023). https://doi.org/10.1007/s10143-023-02112-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10143-023-02112-2

Keywords

Search

Navigation